These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26043205)

  • 1. GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.
    Ahmed MR; Bychkov E; Li L; Gurevich VV; Gurevich EV
    Sci Rep; 2015 Jun; 5():10920. PubMed ID: 26043205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
    Ahmed MR; Jayakumar M; Ahmed MS; Zamaleeva AI; Tao J; Li EH; Job JK; Pittenger C; Ohtsu H; Rajadas J
    Neurobiol Aging; 2019 Sep; 81():177-189. PubMed ID: 31306812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
    Ahmed MR; Bychkov E; Kook S; Zurkovsky L; Dalby KN; Gurevich EV
    Exp Neurol; 2015 Apr; 266():42-54. PubMed ID: 25687550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
    Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
    Gold SJ; Hoang CV; Potts BW; Porras G; Pioli E; Kim KW; Nadjar A; Qin C; LaHoste GJ; Li Q; Bioulac BH; Waugh JL; Gurevich E; Neve RL; Bezard E
    J Neurosci; 2007 Dec; 27(52):14338-48. PubMed ID: 18160641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Ahmed MR; Berthet A; Bychkov E; Porras G; Li Q; Bioulac BH; Carl YT; Bloch B; Kook S; Aubert I; Dovero S; Doudnikoff E; Gurevich VV; Gurevich EV; Bezard E
    Sci Transl Med; 2010 Apr; 2(28):28ra28. PubMed ID: 20410529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
    Altwal F; Moon C; West AR; Steiner H
    Cells; 2020 Oct; 9(10):. PubMed ID: 33050305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
    Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
    Alcacer C; Charbonnier-Beaupel F; Corvol JC; Girault JA; Hervé D
    Neurosci Lett; 2014 Nov; 583():76-80. PubMed ID: 25233866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
    Porras G; De Deurwaerdere P; Li Q; Marti M; Morgenstern R; Sohr R; Bezard E; Morari M; Meissner WG
    Sci Rep; 2014 Jan; 4():3730. PubMed ID: 24429495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.